Back to resultsA Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk (TOGETHER)
Primary Purpose
Dyslipidemia, Hypertension
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Amlodipine besylate
Amlodipine besylate/atorvastatin calcium single pill combination
Amlodipine besylate
Amlodipine besylate/atorvastatin calcium single pill combination
Sponsored by
About this trial
This is an interventional treatment trial for Dyslipidemia
Eligibility Criteria
Inclusion Criteria:
- Subjects with diagnosed hypertension receiving treatment with Norvasc 5 or 10 mg and who also have 3 additional cardiovascular risk factors, including dyslipidemia.
Exclusion Criteria:
- Subjects who are taking the following prohibited medications within 14 days of screening: lipid-lowering therapy, calcium channel blocker other then Norvasc, >3 antihypertensive agents (including Norvasc)
- Subjects that have not been on a stable dose of Norvasc for at least 4 weeks
- Subjects with a history of coronary heart disease, stroke, or Pulmonary Vascular Disease (PVD)
Sites / Locations
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
- Pfizer Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Experimental
Active Comparator
Experimental
Arm Label
Norvasc 5 mg
Caduet 10/20mg
Norvasc 10 mg
Caduet 5/20mg
Arm Description
Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
Outcomes
Primary Outcome Measures
Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6
Number of subjects reaching dual goal of systolic blood pressure <140 millimeters of mercury (mmHg) and diastolic blood pressue of <90 mmHg and low density lipoprotein-cholesterol(LDL-C) <100 milligrams per deciliter(mg/dL)
Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk
Framingham prediction of absolute 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction [MI] or CHD death) are calculations based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and systolic blood pressure calculated at Week 6. Mean at observation minus mean at baseline.
Secondary Outcome Measures
Subjects With Blood Pressure of <140/90 mmHg and LDL-C <100 mg/dL at Week 4
Subjects achieving both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)-7 blood pressure goal of <140/90 mmHg and the National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP) III Update low density lipoprotein-cholesterol (LDL-C) goal <100 mg/dL at Week 4.
Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 4.
Subjects achieving both JNC-7 blood pressure goal of <140/90 mmHg and NCEP/ATP III LDL-C goal <130 mg/dL at Week 4.
Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 6.
Subjects achieving both JNC-7 blood pressure goal of <140/90 mmHg and NCEP/ATP III LDL-C goal <130 mg/dL at Week 6.
Subjects With LDL-C < 100 mg/dL at Week 4
Subjects Who achieve a goal of LDL-C < 100 mg/dL at Week 4.
Subjects With LDL-C < 100 mg/dL at Week 6
Subjects Who achieve a goal of LDL-C < 100 mg/dL at Week 6.
Subjects With BP < 140/90 mmHg at Week 4
Subjects achieving BP goal of <140/90 mmHg at week 4
Subjects With BP < 140/90 mmHg at Week 6
Subjects achieving BP goal of <140/90 mmHg at week 6
Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).
Mean at observation minus mean at baseline
Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)
Mean at observation minus mean at baseline
Change From Baseline to Week 4 in Pulse Rate
Mean at observation minus mean at baseline measured in beats per minute (bpm).
Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)
Mean change at observation minus mean baseline.
Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)
Change from mean at observation minus mean at baseline
Change From Baseline to Week 6 in Pulse Rate
Mean at observation minus mean at baseline
Change From Baseline in LDL at Week 4.
Change: mean of observation minus mean at baseline.
Change From Baseline in High Density Lipoprotein (HDL) at Week 4.
Mean change at observation minus baseline.
Change in Total Cholesterol (TC) From Baseline to Week 4.
Mean change at observation minus baseline.
Change From Baseline in Triglycerides (TG) to Week 4.
Mean change at observation minus baseline
Change From Baseline in LDL at Week 6.
Mean change at observation minus baseline.
Change From Baseline in HDL at Week 6.
Mean change at observation minus baseline.
Change From Baseline in Total Cholesterol (TC) to Week 6.
Mean change at observation minus baseline.
Change From Baseline in Triglycerides (TG) at Week 6.
Mean change at observation minus mean baseline.
Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.
Framingham prediction of absolute 10-year risk of CHD outcomes (MI or CHD death) are calculations based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol and systolic blood pressure calculated at Week 4. Mean at observation minus mean at baseline.
Full Information
NCT ID
NCT00412113
First Posted
December 13, 2006
Last Updated
January 26, 2021
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00412113
Brief Title
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
Acronym
TOGETHER
Official Title
A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors.
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dyslipidemia, Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
245 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Norvasc 5 mg
Arm Type
Active Comparator
Arm Description
Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
Arm Title
Caduet 10/20mg
Arm Type
Experimental
Arm Description
Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
Arm Title
Norvasc 10 mg
Arm Type
Active Comparator
Arm Description
Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
Arm Title
Caduet 5/20mg
Arm Type
Experimental
Arm Description
Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
Intervention Type
Drug
Intervention Name(s)
Amlodipine besylate
Intervention Description
Amlodipine besylate 5 mg
Intervention Type
Drug
Intervention Name(s)
Amlodipine besylate/atorvastatin calcium single pill combination
Intervention Description
Amlodipine/atorvastatin single pill combination 10/20 mg
Intervention Type
Drug
Intervention Name(s)
Amlodipine besylate
Intervention Description
Amlodipine besylate 10 mg
Intervention Type
Drug
Intervention Name(s)
Amlodipine besylate/atorvastatin calcium single pill combination
Intervention Description
Amlodipine/atorvastatin single pill combination 5/20 mg
Primary Outcome Measure Information:
Title
Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6
Description
Number of subjects reaching dual goal of systolic blood pressure <140 millimeters of mercury (mmHg) and diastolic blood pressue of <90 mmHg and low density lipoprotein-cholesterol(LDL-C) <100 milligrams per deciliter(mg/dL)
Time Frame
Week 6
Title
Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk
Description
Framingham prediction of absolute 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction [MI] or CHD death) are calculations based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and systolic blood pressure calculated at Week 6. Mean at observation minus mean at baseline.
Time Frame
Week 6, baseline
Secondary Outcome Measure Information:
Title
Subjects With Blood Pressure of <140/90 mmHg and LDL-C <100 mg/dL at Week 4
Description
Subjects achieving both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)-7 blood pressure goal of <140/90 mmHg and the National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP) III Update low density lipoprotein-cholesterol (LDL-C) goal <100 mg/dL at Week 4.
Time Frame
Week 4
Title
Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 4.
Description
Subjects achieving both JNC-7 blood pressure goal of <140/90 mmHg and NCEP/ATP III LDL-C goal <130 mg/dL at Week 4.
Time Frame
Week 4
Title
Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 6.
Description
Subjects achieving both JNC-7 blood pressure goal of <140/90 mmHg and NCEP/ATP III LDL-C goal <130 mg/dL at Week 6.
Time Frame
Week 6
Title
Subjects With LDL-C < 100 mg/dL at Week 4
Description
Subjects Who achieve a goal of LDL-C < 100 mg/dL at Week 4.
Time Frame
Week 4
Title
Subjects With LDL-C < 100 mg/dL at Week 6
Description
Subjects Who achieve a goal of LDL-C < 100 mg/dL at Week 6.
Time Frame
Week 6
Title
Subjects With BP < 140/90 mmHg at Week 4
Description
Subjects achieving BP goal of <140/90 mmHg at week 4
Time Frame
Week 4
Title
Subjects With BP < 140/90 mmHg at Week 6
Description
Subjects achieving BP goal of <140/90 mmHg at week 6
Time Frame
Week 6
Title
Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).
Description
Mean at observation minus mean at baseline
Time Frame
Week 4, baseline
Title
Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)
Description
Mean at observation minus mean at baseline
Time Frame
Week 4, baseline
Title
Change From Baseline to Week 4 in Pulse Rate
Description
Mean at observation minus mean at baseline measured in beats per minute (bpm).
Time Frame
Week 4, baseline
Title
Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)
Description
Mean change at observation minus mean baseline.
Time Frame
Week 6, baseline
Title
Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)
Description
Change from mean at observation minus mean at baseline
Time Frame
Week 6, baseline
Title
Change From Baseline to Week 6 in Pulse Rate
Description
Mean at observation minus mean at baseline
Time Frame
Week 6, baseline
Title
Change From Baseline in LDL at Week 4.
Description
Change: mean of observation minus mean at baseline.
Time Frame
Week 4, baseline
Title
Change From Baseline in High Density Lipoprotein (HDL) at Week 4.
Description
Mean change at observation minus baseline.
Time Frame
Week 4, baseline
Title
Change in Total Cholesterol (TC) From Baseline to Week 4.
Description
Mean change at observation minus baseline.
Time Frame
Week 4, baseline
Title
Change From Baseline in Triglycerides (TG) to Week 4.
Description
Mean change at observation minus baseline
Time Frame
Week 4, baseline
Title
Change From Baseline in LDL at Week 6.
Description
Mean change at observation minus baseline.
Time Frame
Week 6, baseline
Title
Change From Baseline in HDL at Week 6.
Description
Mean change at observation minus baseline.
Time Frame
Week 6, baseline
Title
Change From Baseline in Total Cholesterol (TC) to Week 6.
Description
Mean change at observation minus baseline.
Time Frame
Week 6, baseline
Title
Change From Baseline in Triglycerides (TG) at Week 6.
Description
Mean change at observation minus mean baseline.
Time Frame
Week 6 , baseline
Title
Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.
Description
Framingham prediction of absolute 10-year risk of CHD outcomes (MI or CHD death) are calculations based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol and systolic blood pressure calculated at Week 4. Mean at observation minus mean at baseline.
Time Frame
Week 4, baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects with diagnosed hypertension receiving treatment with Norvasc 5 or 10 mg and who also have 3 additional cardiovascular risk factors, including dyslipidemia.
Exclusion Criteria:
Subjects who are taking the following prohibited medications within 14 days of screening: lipid-lowering therapy, calcium channel blocker other then Norvasc, >3 antihypertensive agents (including Norvasc)
Subjects that have not been on a stable dose of Norvasc for at least 4 weeks
Subjects with a history of coronary heart disease, stroke, or Pulmonary Vascular Disease (PVD)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Pfizer Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
Pfizer Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35216
Country
United States
Facility Name
Pfizer Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35234
Country
United States
Facility Name
Pfizer Investigational Site
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85206
Country
United States
Facility Name
Pfizer Investigational Site
City
Garden Grove
State/Province
California
ZIP/Postal Code
92843
Country
United States
Facility Name
Pfizer Investigational Site
City
Mission Viejo
State/Province
California
ZIP/Postal Code
92692
Country
United States
Facility Name
Pfizer Investigational Site
City
Rancho Santa Margarita
State/Province
California
ZIP/Postal Code
92688
Country
United States
Facility Name
Pfizer Investigational Site
City
Torrance
State/Province
California
ZIP/Postal Code
90502
Country
United States
Facility Name
Pfizer Investigational Site
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32605
Country
United States
Facility Name
Pfizer Investigational Site
City
Kissimmee
State/Province
Florida
ZIP/Postal Code
34741
Country
United States
Facility Name
Pfizer Investigational Site
City
Melbourne
State/Province
Florida
ZIP/Postal Code
32935
Country
United States
Facility Name
Pfizer Investigational Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Pfizer Investigational Site
City
Safety Harbor
State/Province
Florida
ZIP/Postal Code
34695
Country
United States
Facility Name
Pfizer Investigational Site
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33701
Country
United States
Facility Name
Pfizer Investigational Site
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30904
Country
United States
Facility Name
Pfizer Investigational Site
City
Tucker
State/Province
Georgia
ZIP/Postal Code
30084
Country
United States
Facility Name
Pfizer Investigational Site
City
South Bend
State/Province
Indiana
ZIP/Postal Code
46601
Country
United States
Facility Name
Pfizer Investigational Site
City
Erlanger
State/Province
Kentucky
ZIP/Postal Code
41018
Country
United States
Facility Name
Pfizer Investigational Site
City
Auburn
State/Province
Maine
ZIP/Postal Code
04210
Country
United States
Facility Name
Pfizer Investigational Site
City
Warren
State/Province
Michigan
ZIP/Postal Code
48091
Country
United States
Facility Name
Pfizer Investigational Site
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55404
Country
United States
Facility Name
Pfizer Investigational Site
City
Chesterfield
State/Province
Missouri
ZIP/Postal Code
63017
Country
United States
Facility Name
Pfizer Investigational Site
City
Florissant
State/Province
Missouri
ZIP/Postal Code
63031
Country
United States
Facility Name
Pfizer Investigational Site
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68116-2004
Country
United States
Facility Name
Pfizer Investigational Site
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89014
Country
United States
Facility Name
Pfizer Investigational Site
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89015
Country
United States
Facility Name
Pfizer Investigational Site
City
Belvidere
State/Province
New Jersey
ZIP/Postal Code
07823
Country
United States
Facility Name
Pfizer Investigational Site
City
Bridgewater
State/Province
New Jersey
ZIP/Postal Code
08807
Country
United States
Facility Name
Pfizer Investigational Site
City
Clifton
State/Province
New Jersey
ZIP/Postal Code
07013
Country
United States
Facility Name
Pfizer Investigational Site
City
Elizabeth
State/Province
New Jersey
ZIP/Postal Code
07202
Country
United States
Facility Name
Pfizer Investigational Site
City
Hillsborough
State/Province
New Jersey
ZIP/Postal Code
08844
Country
United States
Facility Name
Pfizer Investigational Site
City
Trenton
State/Province
New Jersey
ZIP/Postal Code
08618
Country
United States
Facility Name
Pfizer Investigational Site
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11229
Country
United States
Facility Name
Pfizer Investigational Site
City
Buffalo
State/Province
New York
ZIP/Postal Code
14209
Country
United States
Facility Name
Pfizer Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Pfizer Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Pfizer Investigational Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
Facility Name
Pfizer Investigational Site
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74136
Country
United States
Facility Name
Pfizer Investigational Site
City
Bensalem
State/Province
Pennsylvania
ZIP/Postal Code
19020
Country
United States
Facility Name
Pfizer Investigational Site
City
Lansdale
State/Province
Pennsylvania
ZIP/Postal Code
19446
Country
United States
Facility Name
Pfizer Investigational Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19146
Country
United States
Facility Name
Pfizer Investigational Site
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02904
Country
United States
Facility Name
Pfizer Investigational Site
City
Goose Creek
State/Province
South Carolina
ZIP/Postal Code
29445
Country
United States
Facility Name
Pfizer Investigational Site
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
Facility Name
Pfizer Investigational Site
City
Bristol
State/Province
Tennessee
ZIP/Postal Code
37620
Country
United States
Facility Name
Pfizer Investigational Site
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
Pfizer Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75235
Country
United States
Facility Name
Pfizer Investigational Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-2324
Country
United States
Facility Name
Pfizer Investigational Site
City
Plano
State/Province
Texas
ZIP/Postal Code
75093
Country
United States
Facility Name
Pfizer Investigational Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78238
Country
United States
Facility Name
Pfizer Investigational Site
City
Chesapeake
State/Province
Virginia
ZIP/Postal Code
23320
Country
United States
12. IPD Sharing Statement
Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3841045&StudyName=A%20Multi-Risk%20Factor%20Strategy%20Vs%20A%20Guideline-Based%20Approach%20In%20Achieving%20Blood%20Pressure%20%26%20Lipid%20Goals%20In%20Hypertensives%20At%20Extra%20Risk
Description
To obtain contact information for a study center near you, click here.
Learn more about this trial
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
We'll reach out to this number within 24 hrs